

Annex H. Indicative non-binding estimated quantities

<u>Table n°1</u>. Total estimated quantities of bedaquiline 100mg to be procured via GDF in basic units (tablets) for the period 15 August 2023 to 31 December 2024 per category of demand:

Item No.	Product description*	Total estimated quantities to be procured via GDF, rounded (in basic units, tablets)				
	Schedule 4: Bedaquiline 100mg demand for all suppliers**					
1+2	Bdq-100-(L) and/or Bdq-100-(B)	7 000 000				

Schedule 5: Bedaquiline 100mg demand for originator product only				
1+2	Bdq-100-(L) and/or Bdq-100-(B)	4 000 000		

^{*} For detailed product specifications please refer to Annex B of the ITB document.

<u>Table n°2.</u> Projection of the quantities of bedaquiline 100mg likely to be procured via GDF per quarter for Schedules 4 and 5 for the total estimated quantities (in Table n°1).

Schedule number and	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
name	Estimated quantities to be procured via GDF (in basic units, tablets)					
Schedule 4: Bedaquiline 100mg demand for all suppliers	1 000 000	400 000	2 500 000	2 300 000	500 000	300 000
Schedule 5: Bedaquiline 100mg demand for originator product only	2 000 000	0	1 500 000	0	500 000	0

This information is based on the best available information at the time of the tender publication. This information is provided for planning purposes only. Actual procurement may not align with these projections. These projections do not bind GDF to any procurement.

<u>Table n°3.</u> Potential additional quantities of bedaquiline 100mg for the period 15 August 2023 to 31 December 2024, which may or may not be procured through GDF based on country decision.

Category of demand	Estimated quantities (in basic units, tablets)	
Potential additional quantities of bedaquiline 100mg for all suppliers	11 500 000	
Potential additional quantities of bedaquiline 100mg for originator product only	5 500 000	

^{**} Originator and generics